title: The role of muscarinic receptors in the beneficial effects of adenosine against myocardial reperfusion injury in rats.
abstract: Adenosine, a catabolite of ATP, displays a wide variety of effects in the heart including regulation of cardiac response to myocardial ischemia and reperfusion injury. Nonetheless, the precise mechanism of adenosine-induced cardioprotection is still elusive. Isolated Sprague-Dawley rat hearts underwent 30 min global ischemia and 120 min reperfusion using a Langendorff apparatus. Both adenosine and acetylcholine treatment recovered the post-reperfusion cardiac function associated with adenosine and muscarinic receptors activation. Simultaneous administration of adenosine and acetylcholine failed to exert any additive protective effect, suggesting a shared mechanism between the two. Our data further revealed a cross-talk between the adenosine and acetylcholine receptor signaling in reperfused rat hearts. Interestingly, the selective M(2) muscarinic acetylcholine receptor antagonist methoctramine significantly attenuated the cardioprotective effect of adenosine. In addition, treatment with adenosine upregulated the expression and the maximal binding capacity of muscarinic acetylcholine receptor, which were inhibited by the selective A(1) adenosine receptor antagonist 8-Cyclopentyl-1,3-dipropylxanthine (DPCPX) and the nitric oxide synthase inhibitor N(ω)-nitro-L-arginine methyl ester (L-NAME). These data suggested a possible functional coupling between the adenosine and muscarinic receptors behind the observed cardioprotection. Furthermore, nitric oxide was found involved in triggering the response to each of the two receptor agonist. In summary, there may be a cross-talk between the adenosine and muscarinic receptors in ischemic/reperfused myocardium with nitric oxide synthase might serve as the distal converging point. In addition, adenosine contributes to the invigorating effect of adenosine on muscarinic receptor thereby prompting to regulation of cardiac function. These findings argue for a potentially novel mechanism behind the adenosine-mediated cardioprotection.
authors.affiliation: Department of Pharmacology, College of Medicine, Xi'an Jiaotong University, Xi'an, China.
authors.forename: Lei
authors.initials: L
authors.lastname: Sun
authors.forename: Dong-Ling
authors.initials: DL
authors.lastname: Li
authors.forename: Mei
authors.initials: M
authors.lastname: Zhao
authors.forename: Xi
authors.initials: X
authors.lastname: He
authors.forename: Xiao-Jiang
authors.initials: XJ
authors.lastname: Yu
authors.forename: Yi
authors.initials: Y
authors.lastname: Miao
authors.forename: Hao
authors.initials: H
authors.lastname: Wang
authors.forename: Jun
authors.initials: J
authors.lastname: Ren
authors.forename: Wei-Jin
authors.initials: WJ
authors.lastname: Zang
mesh_terms: D000109:Acetylcholine / Q000008:administration & dosage; D000241:Adenosine / Q000008:administration & dosage / Q000627:therapeutic use*; D000818:Animals; D066298:In Vitro Techniques; D008297:Male; D015428:Myocardial Reperfusion Injury / Q000517:prevention & control*; D011869:Radioligand Assay; D051381:Rats; D017207:Rats, Sprague-Dawley; D011976:Receptors, Muscarinic / Q000502:physiology*
chemical_list: D011976:Receptors, Muscarinic; D000241:Adenosine; D000109:Acetylcholine
references.citation: J Cardiovasc Pharmacol Ther. 2012 Mar;17(1):21-33
references.pmid: 21335481
references.citation: Cardiovasc Res. 2005 Jul 1;67(1):124-33
references.pmid: 15949476
references.citation: Heart Fail Rev. 2011 Mar;16(2):195-203
references.pmid: 21165697
references.citation: Heart Vessels. 2003 Mar;18(1):26-31
references.pmid: 12644878
references.citation: Am J Physiol Heart Circ Physiol. 2000 Nov;279(5):H2166-75
references.pmid: 11045950
references.citation: Nat Rev Drug Discov. 2006 Mar;5(3):247-64
references.pmid: 16518376
references.citation: J Pharmacol Sci. 2011;115(2):205-213
references.pmid: 32272538
references.citation: Neurochem Int. 2001 Feb;38(2):107-25
references.pmid: 11137880
references.citation: Handb Exp Pharmacol. 2009;(193):161-88
references.pmid: 19639282
references.citation: Cardiovasc Res. 2005 Mar 1;65(4):803-12
references.pmid: 15721860
references.citation: Circ Res. 1993 Dec;73(6):1193-201
references.pmid: 8222090
references.citation: J Cardiovasc Pharmacol. 2007 May;49(5):287-92
references.pmid: 17513947
references.citation: J Cardiovasc Pharmacol. 1999 Dec;34(6):904-12
references.pmid: 10598137
references.citation: J Am Coll Cardiol. 1993 Mar 1;21(3):655-61
references.pmid: 8436747
references.citation: Biochim Biophys Acta. 2011 May;1808(5):1413-28
references.pmid: 21094127
references.citation: Circulation. 2008 Sep 30;118(14 Suppl):S32-7
references.pmid: 18824766
references.citation: J Cell Physiol. 2007 Dec;213(3):785-92
references.pmid: 17516542
references.citation: Circulation. 2008 Aug 19;118(8):863-71
references.pmid: 18711023
references.citation: J Physiol. 2003 Dec 1;553(Pt 2):445-56
references.pmid: 12972626
references.citation: Z Kardiol. 2004 Oct;93(10):768-83
references.pmid: 15492892